查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878856

基於電動車的液體活體組織切片市場－全球產業規模、佔有率、趨勢、機會和預測，按產品、工作流程、技術、樣本類型、最終用戶、地區和競爭格局細分，2020-2030 年預測

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Workflow, By Technology, By Sample Type, By End user, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球以細胞外囊泡（EV）為基礎的液體活體組織切片市場規模為9,112萬美元，預計到2030年將以9.74%的複合年成長率成長至1.5914億美元。基於細胞外囊泡的液體活體組織切片技術是對包裹在細胞外囊泡（例如外泌體）內的疾病特異性生物標記進行非侵入性分析，這些囊泡存在於血液或尿液等體液中。這些囊泡攜帶包括蛋白質、核酸和脂質在內的分子物質，能夠提供有關來源細胞生理和病理狀態的資訊。慢性疾病（尤其是癌症）在全球日益加重，以及對早期、非侵入性診斷解決方案的需求不斷成長，是推動該市場擴張的主要因素。此外，EV在生物體液中固有的穩定性和豐富性，使其優於其他循環生物標記物，也是促進市場成長的關鍵因素。

市場概覽
預測期 2026-2030
2024年市場規模 9112萬美元
2030年市場規模 1.5914億美元
2025-2030年複合年成長率 9.74%
成長最快的細分市場 試劑盒和檢測
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球基於電動車的液體切片市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過提供（試劑盒和檢測、服務、儀器）
    • 依工作流程（樣品製備、定序、數據分析）
    • 依技術分類（隔離技術、分析技術）
    • 依樣本類型（血液、尿液、唾液、其他）
    • 按最終用戶（學術和研究機構、製藥和生物技術公司、臨床實驗室）分類
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美電動車液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲電動車液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區以電動車為基礎的液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基於電動車的液體活體組織切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲電動車液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球以電動車為基礎的液體切片市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen NV
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 15834

The Global EV-Based Liquid Biopsy Market , valued at USD 91.12 Million in 2024, is projected to experience a CAGR of 9.74% to reach USD 159.14 Million by 2030. Extracellular vesicle (EV)-based liquid biopsy involves the non-invasive analysis of disease-specific biomarkers encapsulated within extracellular vesicles, such as exosomes, circulating in bodily fluids like blood or urine. These vesicles carry molecular cargoes including proteins, nucleic acids, and lipids, providing insights into the physiological and pathological state of originating cells. The market's expansion is significantly driven by the increasing global burden of chronic diseases, particularly cancer, and the rising demand for early, non-invasive diagnostic solutions. The inherent stability and abundance of EVs in biofluids, offering advantages over other circulating biomarkers, also act as key growth facilitators.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 91.12 Million
Market Size 2030USD 159.14 Million
CAGR 2025-20309.74%
Fastest Growing SegmentKits & Assays
Largest MarketNorth America

Key Market Drivers

The escalating global cancer burden fundamentally drives the EV-based liquid biopsy market. Traditional diagnostic methods often face limitations in early detection and continuous monitoring, areas where the non-invasive nature of EV liquid biopsies offers significant advantages. As cancer incidence continues its upward trajectory, the urgency for advanced, accessible diagnostic tools intensifies. According to the International Agency for Research on Cancer (IARC), in 2022, there were close to 20 million new cases of cancer worldwide. This pervasive health crisis necessitates innovative solutions that can accurately identify malignancies at earlier stages and monitor treatment efficacy without the invasiveness of tissue biopsies, directly propelling the adoption and development of EV-based platforms.

Key Market Challenges

A substantial challenge impeding the growth of the Global EV-Based Liquid Biopsy Market is the ongoing technical complexity associated with isolating and comprehensively characterizing extracellular vesicles (EVs) from complex biofluids. This inherent variability in isolation methods and subsequent characterization protocols often leads to significant issues with reproducibility and consistent clinical validation. The lack of standardized procedures across different laboratories and platforms directly compromises the reliability of test results, creating skepticism among clinicians and delaying the widespread adoption of EV-based diagnostic solutions.

Key Market Trends

The emergence of novel EV biomarkers is significantly shaping the global EV-based liquid biopsy market by enhancing diagnostic precision and expanding application areas. Research into disease-specific cargo within extracellular vesicles, such as proteins and nucleic acids, is uncovering new targets for early detection and disease monitoring across various pathologies. This focus on biomarker discovery drives the development of more sensitive and specific diagnostic assays. According to the International Society for Extracellular Vesicles, its MISEV2023 guidelines, published in March 2024, garnered consensus from approximately 97% of surveyed members, reflecting a widespread scientific commitment to standardizing and advancing EV research which underpins biomarker identification. This collective effort is crucial for translating promising biomarker candidates into validated clinical tools. Furthermore, a review article in *Biology (Basel)* in September 2024, highlighted the therapeutic opportunity of tumor-derived extracellular vesicles, emphasizing their capacity to harbor cancer-derived cargo reflective of their cell-of-origin and their superior stability in blood for diagnostic and prognostic insights.

Key Market Players

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

EV-Based Liquid Biopsy Market , By Offering:

  • Kits & Assays
  • Services
  • Instruments

EV-Based Liquid Biopsy Market , By Workflow:

  • Sample Preparation
  • Sequencing
  • Data Analysis

EV-Based Liquid Biopsy Market , By Technology:

  • Isolation Technologies
  • Analysis Technologies

EV-Based Liquid Biopsy Market , By Sample Type:

  • Blood
  • Urine
  • Saliva
  • Others

EV-Based Liquid Biopsy Market , By End User:

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Clinical Laboratories

EV-Based Liquid Biopsy Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global EV-Based Liquid Biopsy Market .

Available Customizations:

Global EV-Based Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global EV-Based Liquid Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering (Kits & Assays, Services, Instruments)
    • 5.2.2. By Workflow (Sample Preparation, Sequencing, Data Analysis)
    • 5.2.3. By Technology (Isolation Technologies, Analysis Technologies)
    • 5.2.4. By Sample Type (Blood, Urine, Saliva, Others)
    • 5.2.5. By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America EV-Based Liquid Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering
    • 6.2.2. By Workflow
    • 6.2.3. By Technology
    • 6.2.4. By Sample Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States EV-Based Liquid Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Sample Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada EV-Based Liquid Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Sample Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico EV-Based Liquid Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Sample Type
        • 6.3.3.2.5. By End User

7. Europe EV-Based Liquid Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering
    • 7.2.2. By Workflow
    • 7.2.3. By Technology
    • 7.2.4. By Sample Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany EV-Based Liquid Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Sample Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France EV-Based Liquid Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Sample Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom EV-Based Liquid Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Sample Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy EV-Based Liquid Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Sample Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain EV-Based Liquid Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Sample Type
        • 7.3.5.2.5. By End User

8. Asia Pacific EV-Based Liquid Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering
    • 8.2.2. By Workflow
    • 8.2.3. By Technology
    • 8.2.4. By Sample Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China EV-Based Liquid Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Sample Type
        • 8.3.1.2.5. By End User
    • 8.3.2. India EV-Based Liquid Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Sample Type
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan EV-Based Liquid Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Sample Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea EV-Based Liquid Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Sample Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia EV-Based Liquid Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Sample Type
        • 8.3.5.2.5. By End User

9. Middle East & Africa EV-Based Liquid Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering
    • 9.2.2. By Workflow
    • 9.2.3. By Technology
    • 9.2.4. By Sample Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia EV-Based Liquid Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Sample Type
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE EV-Based Liquid Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Sample Type
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa EV-Based Liquid Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Sample Type
        • 9.3.3.2.5. By End User

10. South America EV-Based Liquid Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering
    • 10.2.2. By Workflow
    • 10.2.3. By Technology
    • 10.2.4. By Sample Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil EV-Based Liquid Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Sample Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia EV-Based Liquid Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Sample Type
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina EV-Based Liquid Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Sample Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global EV-Based Liquid Biopsy Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Horiba Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Lonza Group AG
  • 15.4. Takara Bio Inc.
  • 15.5. Abcam plc
  • 15.6. Qiagen N.V.
  • 15.7. Malvern Panalytical Ltd.
  • 15.8. Revvity, Inc. (PerkinElmer, Inc)
  • 15.9. Norgen Biotek Corp.
  • 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer